Hualan Biological Bacterin Inc
SZSE:301207
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
15.63
31.68
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Hualan Biological Bacterin Inc
Cost of Revenue
Hualan Biological Bacterin Inc
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
H
|
Hualan Biological Bacterin Inc
SZSE:301207
|
Cost of Revenue
-¥382m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
N/A
|
|
|
Beigene Ltd
HKEX:6160
|
Cost of Revenue
-¥2.7B
|
CAGR 3-Years
-77%
|
CAGR 5-Years
-70%
|
CAGR 10-Years
N/A
|
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Cost of Revenue
-¥992.7m
|
CAGR 3-Years
-28%
|
CAGR 5-Years
-29%
|
CAGR 10-Years
N/A
|
|
|
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
|
Cost of Revenue
-¥5B
|
CAGR 3-Years
-54%
|
CAGR 5-Years
-46%
|
CAGR 10-Years
-33%
|
|
|
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Cost of Revenue
-¥35.1B
|
CAGR 3-Years
-49%
|
CAGR 5-Years
-51%
|
CAGR 10-Years
-62%
|
|
|
Imeik Technology Development Co Ltd
SZSE:300896
|
Cost of Revenue
-¥140.8m
|
CAGR 3-Years
-36%
|
CAGR 5-Years
-32%
|
CAGR 10-Years
N/A
|
|
Hualan Biological Bacterin Inc
Glance View
Hualan Biological Bacterin Inc is a CN-based company operating in Biotechnology industry. The company is headquartered in Xinxiang, Henan and currently employs 917 full-time employees. The company went IPO on 2022-02-18. Hualan Biological Bacterin Inc is a China-based company specializing in the research, development, production and sales of human vaccines. The firm's listed products mainly include influenza virus split vaccine, quadrivalent influenza virus split vaccine, influenza A H1N1 split vaccine, recombinant hepatitis B vaccine and others. The firm's products that have been approved for clinical trials or have passed clinical registration and are pending for marketing mainly include human rabies vaccines, adsorbed tetanus vaccines, H7N9 influenza whole virus inactivated vaccines and others. The firm's products in the preclinical research stage include inactivated new coronavirus vaccine, freeze-dried nasal spray recombinant new coronavirus live attenuated vaccine and others.
See Also
What is Hualan Biological Bacterin Inc's Cost of Revenue?
Cost of Revenue
-382m
CNY
Based on the financial report for Dec 31, 2023, Hualan Biological Bacterin Inc's Cost of Revenue amounts to -382m CNY.
What is Hualan Biological Bacterin Inc's Cost of Revenue growth rate?
Cost of Revenue CAGR 5Y
-21%
Over the last year, the Cost of Revenue growth was -3%. The average annual Cost of Revenue growth rates for Hualan Biological Bacterin Inc have been -10% over the past three years , -21% over the past five years .
You don't have any saved screeners yet
